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The bioreductive antitumour agent, mitomycin C (MMC), requires activation by reductive enzymes like NAD(P)H:quinone
oxidoreductase 1 (NQO1). We used a novel approach to increase MMC efficacy by selectively inducing NQO1 in tumour cells in
vivo. CD-1 nude mice were implanted with HCT116 cells, and fed control diet or diet containing 0.3% of the NQO1 inducer,
dimethyl fumarate (DMF). The mice were then treated with saline, 2.0, 3.5 or 2.0mgkg
 1 MMC and dicoumarol, an NQO1 inhibitor.
The DMF diet increased NQO1 activity by 2.5-fold in the tumours, but had no effect in marrow cells. Mice given control diet/
2.0mgkg
 1 MMC had tumours with the same volume as control mice; however, mice given DMF diet/2.0mgkg
 1 MMC had
significantly smaller tumours. Tumour volumes in mice given DMF/2.0mgkg
 1 MMC were similar to those in mice given control diet/
3.5mgkg
 1 MMC. Tumour inhibition was partially reversed in mice given DMF/2.0mgkg
 1 MMC and dicoumarol. DMF diet/
2.0mgkg
 1 MMC treatment did not increase myelosuppression and did not produce any organ toxicity. These results provide strong
evidence that dietary inducers of NQO1 can increase the antitumour activity of bioreductive agents like MMC without increasing
toxicity.
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Bioreductive agents are a class of anticancer drugs that must be
activated in cells by reduction. These agents are preferentially
active in solid tumours, which represent the majority of cancers
and the highest mortality. The clinical potential (Workman and
Stratford, 1993) and mode of action (Rauth et al, 1993; Rockwell
et al, 1993) of these agents have been actively studied, and the use
of the prototype drug mitomycin C (MMC) in the clinic was
recently reviewed (Begleiter, 2000). Bioreductive agents are
generally activated by one-electron reducing enzymes like
NADPH:cytochrome P450 reductase (RED) (Pan et al, 1984;
Rockwell et al, 1993) or two-electron reducing enzymes like
NAD(P)H:quinone oxidoreductase 1 (NQO1; DT-diaphorase)
(Riley and Workman, 1992; Ross et al, 1993). RED and NQO1
are the major activators for current agents (Begleiter et al, 1989,
1992; Hoban et al, 1990; Riley and Workman, 1992; Begleiter and
Leith, 1993; Ross et al, 1993; Patterson et al, 1995), but their role
varies with the agent, enzyme, oxygen level (Marshall et al, 1989;
Hoban et al, 1990; Begleiter et al, 1992) and pH (Siegel et al, 1990;
Begleiter and Leith, 1993). Reduction of MMC activates alkylating
groups that form DNA crosslinks, and this is the most important
cytotoxic mechanism for this agent (Lown et al, 1976; Pan et al,
1986; Tomasz et al, 1987; Riley and Workman, 1992). However,
in the presence of oxygen, redox cycling occurs to form reactive
oxygen species, which can also contribute to cytotoxic activity
(Lown et al, 1976; Dusre et al, 1989; Riley and Workman, 1992).
NQO1 catalyses two-electron reduction of quinones and
nitrogen-oxides (Ernster, 1987; Riley and Workman, 1992). Several
human diaphorases are known (Jaiswal et al, 1990, 1991; Riley and
Workman, 1992), but NQO1 is most important for activating
bioreductive agents (Jaiswal, 1991; Riley and Workman, 1992;
Belinsky and Jaiswal, 1993). NQO1 is a homodimer that uses
NAD(P)H as an electron donor (Riley and Workman, 1992). The
enzyme is mainly cytosolic, but 5–10% is membrane bound (Riley
and Workman, 1992). It is ubiquitous in eukaryotes but levels vary
in different tissues (Schlager and Powis, 1990; Riley and Workman,
1992; Belinsky and Jaiswal, 1993), with low levels in haematopoetic
cells (Schlager and Powis, 1990; Siegel et al, 2001). NQO1 activity is
usually higher in tumour than normal cells, but is lower in vivo
than in vitro (Schlager and Powis, 1990; Riley and Workman, 1992;
Belinsky and Jaiswal, 1993; Ross et al, 1994; Collard et al, 1995).
Expression of NQO1 is transcriptionally regulated (Riley and
Workman, 1992), and the enzyme is highly inducible by a wide
variety of inducers (Prestera et al, 1993). The induction pathway is
unknown but may involve a cytosolic redox signal that alters
expression and/or interaction of transcriptional factors like Jun,
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sNrf, Maf, Fos and Fra with the xenobiotic response element and the
antioxidant response element (Belinsky and Jaiswal, 1993; Favreau
and Pickett, 1993; Venugopal and Jaiswal, 1996, 1998; Yao et al,
1996; Kepa and Ross, 1999; Nguyen et al, 2000). An NF-kB element
may also be involved in induction (Yao and O’Dwyer, 1995). NQO1
is induced by a wide variety of dietary and synthetic agents
including: dithiolethiones like Oltipraz, an antiparasitic agent;
isothiocyanates like sulforaphane, found in cruciferous vegetables,
and dietary metabolites like dimethyl fumarate (DMF), a
metabolite of fumaric acid which is found in fruits and vegetables
(Talalay et al, 1988; Prestera et al, 1993). NQO1 is a member of the
phase II detoxifying enzymes that help to remove xenobiotics from
cells and are important in early defence against carcinogenesis
(Prestera et al, 1993). Inducers of NQO1 like Oltipraz have been
tested as cancer preventive agents in animals and humans (Egner
et al, 1994; Hecht, 1998; Kensler et al, 1998).
Activation of MMC by NQO1 has been extensively studied (Riley
and Workman, 1992; Ross et al, 1993). Cells with elevated NQO1
levels are more sensitive to MMC and drug activity is decreased by
the NQO1 inhibitor, dicoumarol (DIC) (Begleiter et al, 1989;
Marshall et al, 1989; Siegel et al, 1990). NQO1 is a major activating
enzyme for MMC and other bioreductive agents including, RH1
and MeDZQ (Workman and Stratford, 1993; Riley and Workman,
1992; Beall et al, 1995; Winski et al, 1998). Thus, selectively
increasing the level of NQO1 in tumour cells by gene transfer
(Rauth et al, 1998) or by selective induction of NQO1 in tumours
may be useful for enhancing the efficacy of bioreductive agents.
We showed previously that we could selectively increase NQO1
activity in tumour cells compared with normal cells and that this
enhanced MMC antitumour activity in vitro (Doherty et al, 1998;
Wang et al, 1999). In this study we investigated whether we could
selectively induce NQO1 activity in human tumours implanted in a
nude mouse model, and if this would increase the antitumour
activity of bioreductive agents without increasing the toxicity of
these agents.
MATERIALS AND METHODS
Materials
The human colon carcinoma HCT116 cell line was obtained from
ATCC (Manassas, VA, USA) and DMEM/Hams F12 media, foetal
bovine sera and Hanks balanced salt solution (HBSS) were
obtained from Invitrogen (Burlington, ON, Canada). The
HCT116 cells tested negative for mycoplasma contamination.
DMF, MMC and DIC were from Sigma-Aldrich Canada (Oakville,
ON, Canada) as were all reagents for the NQO1 activity assay.
NycoPrep 1.077A was from Cedarlane (Hornby, ON, Canada). Bio-
Rad DC Protein kit was from Bio-Rad (Canada) Ltd (Mississauga,
ON, Canada).
Female CD-1 and CD-1 nude mice (6–8 weeks of age) were
obtained from Charles River Canada (Montreal, QC, Canada) and
were maintained according to institutional regulations. The mice
were fed standard irradiated rodent chow except during
the experimental diet period. The experimental diet for the mice
was a custom powdered autoclavable, semipurified diet with
antioxidant free corn oil and vitamin K instead of menadione
from ICN Biochemical Division (Aurora, OH, USA). Diets with
different concentrations of DMF in the diet were made by the
addition of finely ground DMF to the custom diet followed by
autoclaving.
Microvettes CB 300 with potassium EDTA, used for blood
collection, were obtained from Sarstedt (St Leonard, QC, Canada).
Zap-oglobin II lytic reagent and Isoton II were obtained from
Beckman Coulter (Mississauga, ON, Canada). Ketalean and
Rompum were obtained from Central Animal Care, University of
Manitoba (Winnipeg, MB, Canada).
Cell lines and clonogenic assays
HCT116 cells were grown in DMEM/Hams F12 media and 10%
foetal bovine sera. Clonogenic assays were performed as previously
described (Begleiter and Leith, 1993). Cloning efficiency ranged
from 51 to 90%. Cells were incubated at 371C for 48h in the
presence or absence of 5mM DMF and then were treated with
various concentrations of MMC for 1h. Cells were plated and
colonies were counted 6 days later. A linear regression analysis of
each concentration–survival curve was obtained and the D10 was
derived from the negative reciprocal of the regression slope
(Begleiter et al, 1992). The cytotoxicities were compared statisti-
cally by a t-test comparing the significance of the differences of the
slopes of the concentration–survival curves.
For implantation into CD-1 nude mice, the HCT116 cells were
counted, washed three times in HBSS, assessed for viability with
trypan blue and resuspended at a concentration of 5 10
7 viable
cells per ml in HBSS; 100ml of the cell suspension was injected
subcutaneously into the right flank of each mouse.
NQO1 activity measurements
NQO1 activity was measured as described previously (Doherty
et al, 1998) using menadione as electron acceptor and is reported
as nmol MTT reducedmin
 1mgprotein
 1. Protein was deter-
mined with the Bio-Rad DC kit using gamma-globulin as protein
standard. NQO1 activity was measured in 0.25 M sucrose sonicates
of HCT116 cells, mouse marrow cells and in sonicates of
homogenised mouse tissue. Mouse organs were excised and stored
frozen at  801C in sucrose until analysis. Marrow was obtained by
flushing the mouse femurs with HBSS and pooled from several
mice. The marrow cells were layered over NycoPrep 1.077A and
spun at 600g for 15min; the resulting layer of cells was washed and
frozen at  801C in sucrose until analysis. NQO1 activities in
HCT116 cells in vitro were compared statistically by t-test. In
mouse organs, the NQO1 activities were compared statistically by
Mann–Whitney rank sum test.
Effect of dose and schedule of DMF on induction of NQO1
in vivo
To determine the optimal concentration of DMF in the diet for
NQO1 induction, CD-1 mice were fed experimental diet containing
0, 0.2, 0.3 or 0.4% DMF for 2 weeks. The mice were then killed and
the liver, forestomach and kidney were removed and stored frozen
at  801C in 0.25 M sucrose until analysis for NQO1 activity.
To determine the optimal length of DMF feeding for induction
of NQO1 activity, CD-1 nude mice were implanted subcutaneously
in the right flanks with 5 10
6 HCT116 cells and the mice were fed
custom experimental diet containing no DMF for 18, 15, 11 or 4
days. The mice were then fed experimental diet containing 0.3%
DMF for 0, 3, 7 or 14 days, respectively, prior to killing 18 days
following tumour implantation. The HCT116 xenografts were
approximately 100–250mm
3 at this time. The mice were killed, the
organs (kidney, liver, lung, heart and forestomach) and the
HCT116 xenografts were removed and marrow was obtained. All
tissues were frozen at  801C prior to measurement of NQO1
activity.
In vivo combination treatment studies
For the in vivo combination treatment studies, CD-1 nude mice
were implanted with 5 10
6 HCT116 cells subcutaneously in the
right flank of each mouse. The mice were fed a standard irradiated
mouse diet for the first 7–10 days following tumour implantation
and then randomly switched to the experimental diet containing 0
or 0.3% DMF for a further 7–10 days. At this time, day 0, mice
with tumours measuring approximately 100–250mm
3 were
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srandomly assigned to treatment groups. The mice were weighed
and received a single tail-vein injection of saline (control diet and
0.3% DMF diet), 2.0mgkg
 1 MMC (control diet and 0.3% DMF
diet) or 3.5mgkg
 1 MMC (control diet only). In addition, some
mice on the 0.3% DMF diet received a single i.p injection of
34mgkg
 1 DIC 1h prior to the 2.0mgkg
 1 MMC injection. Some
mice with tumours were killed at day 0 and organs, marrow and
xenografts were removed for measurement of NQO1 activity. On
day 1, the diet for all the mice was switched to the standard
irradiated diet. On days 0, 3, 7, 10, 15 and 18, tumour diameters in
three dimensions were measured using digital calipers, and
tumour volume was calculated by the formula (l w d 0.5236)
(Rockwell et al, 1972). Mouse body weights were also recorded on
these same days. Differences in tumour volumes were analysed
statistically by a t-test comparing the slopes of the regression lines
for plots of tumour volume vs days after MMC treatment in mice
receiving different treatments.
White blood cell (WBC) and platelet counts
On days 0, 3, 6, 9, 12 and 15, approximately 20ml of blood was
collected from the saphenous veins of some of the mice from each
treatment group (Hem et al, 1998). The blood was collected into a
microvette CB 300 with potassium EDTA and 10ml aliquots were
used for the determination of WBC or platelet counts. The counts
were determined with a Coulter Z2 particle count and cell analyser
(Beckman Coulter, Mississauga, ON, Canada). The Coulter Z2
counter was optimised for mouse white blood cells and platelets
according to the manufacturer’s protocols and all counts were
analysed with the Coulter AccuComp software program. WBC were
counted with a 100mm aperture tube (set for a lower threshold of
3mm) following the addition of Zap-oglobin II lytic reagent to the
coulter counter vial (50ml per 10ml Isoton II). For counting of
platelets, 10ml of mouse blood was diluted in 240ml Isoton II and
spun at 83 g for 3min to remove the red blood cells. In total,
100ml of supernatant was then diluted in Isoton II and the platelets
were counted using a 50 or 70mm aperture tube with a lower
threshold of 1.4 fl and an upper threshold of 24.4fl. Differences in
the WBC and platelet counts in different treatment groups were
analysed statistically by ANOVA for each time point.
MMC toxicity in vivo
CD-1 nude mice (n¼3) without tumours were fed a 0 or 0.3%
DMF diet for 7–10 days and then were treated with a single tail-
vein injection of saline (control diet), 2.0mgkg
 1 MMC (control
diet and 0.3% DMF diet). After 7 days, the mice were anesthetised
with Ketalean/Rompum and blood was obtained by cardiac
puncture. The mice were then euthanised with carbon dioxide
and organs were removed and fixed in neutral buffered formalin.
The blood was allowed to clot and the serum was collected
following centrifugation at 1500 g for 15min. The serum was
stored frozen at  801C until analysed. The serum was analysed in a
Roche Hitachi 917 (Health Sciences Centre, Department of Clinical
Chemistry, Winnipeg, MB, Canada) for the following parameters:
Na, K, Cl, blood urea nitrogen, serum creatinine, alkaline
phophatase, alanine transaminase, aspartate transaminase, gam-
ma-glutamyl transpeptidase, lactate dehydrogenase. The organs
were sectioned, stained with haematoxalin and eosin and examined
histologically.
RESULTS
Effect of induction of NQO1 on cytotoxic activity of MMC
in vitro
When HCT116 cells were incubated in vitro with, or without,
DMF, the level of NQO1 activity increased from
94.073.0nmolmin
 1mg
 1protein
 1 in control cells to
194.075.3nmolmin
 1mgprotein
 1 in DMF treated cells
(Po0.001) (Figure 1). Cells that had been pretreated with DMF
and then were treated with MMC were more sensitive to MMC than
cells that did not receive DMF (Figure 1). The D10 for cells treated
with MMC alone was 2.1270.13mM while that for cells treated with
DMF and MMC was 1.5570.43mM, and this difference was
statistically significant (Po0.001).
Effect of dose and schedule of DMF on induction of NQO1
in HCT116 cells in vivo
CD-1 mice were fed a diet containing 0, 0.2, 0.3 or 0.4% DMF for 14
days. NQO1 activities in the kidney, liver and forestomach were
increased in mice fed a diet containing DMF compared to mice
receiving a control diet; however, enzyme activities in mice fed diet
containing 0.3 or 0.4% DMF were not significantly different.
CD-1 nude mice implanted with HCT116 cells received
experimental diet containing 0.3% DMF for 0, 3, 7 or 14 days.
NQO1 activity increased in the implanted tumours and reached a
plateau level at approximately 7 days on the DMF diet (Figure 2).
In contrast, enzyme levels in forestomach, kidney, lung and liver
tissues continued to increase to 14 days on the DMF diet, while
NQO1 activity in heart tissue remained unchanged. NQO1 activity
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Figure 1 Effect of DMF on cytotoxic activity of MMC in HCT116 cells in
vitro. Cells were incubated at 371C for 48h in the absence or presence of
5mM DMF. NQO1 activity was measured in some of the cells, and the
remaining cells were treated with MMC for 1h. Cells were plated and
surviving cell fraction was determined by clonogenic assay. The points
represent the mean surviving cell fraction7s.e. of 5–15 determinations.
The lines are linear regression lines. Inset: level of NQO1 activity in cells
incubated in the absence or presence of DMF. The bars represent the
mean NQO1 activity7s.e. of 8 determinations. The means were
compared by a t-test evaluating the significance of the difference of the
NQO1 activity in control and DMF incubated cells.
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sin bone marrow reached a peak at 3 days on the DMF diet, and
decreased after that time.
Effect of induction of NQO1 on MMC antitumour activity
and toxicity in vivo
CD-1 nude mice implanted with HCT116 cells were fed either
control experimental diet or diet containing 0.3% DMF for 7–10
days. Some mice were euthanised at that time and tumours and
tissues were excised. The remaining mice were weighed, tumour
volumes were measured and blood samples were obtained from
some mice for WBC and platelet counts. The mice were then
treated with saline or DIC, and then with saline, 2.0 or 3.5mgkg
 1
MMC. On various days, tumour volumes were measured and blood
samples were obtained for WBC and platelet counts. Average
tumour volumes on the day of MMC treatment ranged from 132 to
163mm
3 for the different treatment groups and these differences
were not statistically significant. The level of NQO1 increased by
2.5-fold in the tumours and to a similar extent in the kidneys and
forestomach (Po0.001) in mice fed diet containing DMF (Table 1).
In contrast, NQO1 activity increased by 1.4-fold in liver (Po0.02),
but did not increase significantly in bone marrow, lung or
heart.
The tumour volumes increased in all the mice, with the tumour
volume in control mice (mice fed control diet and treated with
saline) increasing by four-fold 18 days after treatment (Figure 3).
Mice fed control diet and treated with 2.0mgkg
 1 MMC showed
the same rate of increase in tumour volume as control mice. In
contrast, the rate of tumour growth in mice fed DMF diet and
treated with 2.0mgkg
 1 MMC was approximately 15% lower than
the rate of tumour growth in control mice or in mice fed control
diet and treated with 2.0mgkg
 1 MMC, and this difference was
statistically significant (Po0.01). Mice fed DMF diet that received
DIC prior to 2.0mgkg
 1 MMC showed a partial reversal of the
enhanced antitumour effect observed in mice fed DMF diet and
treated with 2.0mgkg
 1 MMC. The antitumour effect seen in mice
fed DMF diet and treated with 2.0mgkg
 1 MMC was equivalent to
that observed in mice fed control diet and treated with 3.5mgkg
 1
MMC. DMF diet alone did not inhibit the increase in tumour
volume (data not shown).
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Figure 2 Effect of time on DMF diet on NQO1 activity in human
tumour xenografts and normal tissues in CD-1 nude mice. CD-1 nude mice
were implanted subcutaneously in the right flank with HCT116 cells and
the mice received diet containing 0.3% DMF for 0, 3, 7 or 14 days. The
mice were killed, the organs (kidney, liver, lung, heart, forestomach) and the
HCT116 xenografts were removed and marrow was obtained. For each
tissue, NQO1 activity was measured and is reported as the NQO1 activity
in that tissue as a percent of NQO1 activity in the same tissue in mice fed
diet containing no DMF. The points represent the means of values obtained
from three mice.
Table 1 Effect of DMF diet on NQO1 activity in tumours and normal
tissues
NQO1 activity (nmolmin
 1mgprotein
 1)
Ratio
Tissue Control diet DMF diet DMF/control
Tumour 5975 145710 2.5*
Marrow 13721 7 73 1.4
Kidney 13578 329713 2.4*
Liver 39725 4 72 1.4*
Lung 33754 3 74 1.3
Heart 91758 6 77 0.9
Forestomach 362728 952754 2.6*
CD-1 nude mice implanted with HCT116 tumours were fed a 0 or 0.3% DMF diet
for 7–10 days. Mice were euthanised and NQO1 activity was measured in different
tissues. Data are mean7s.e. of 9–17 mice. NQO1 activity in mice fed control diet
and diet containing DMF were compared by Mann–Whitney rank sum test.
*Po0.05.
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Figure 3 Effect of DMF diet on MMC antitumour activity in HCT116
xenografts in CD-1 nude mice. Mice were implanted with tumour cells
subcutaneously in the right flank of each mouse. After 7–10 days the mice
were fed a diet containing 0 or 0.3% DMF for 7–10 days. The mice were
weighed and received a single tail-vein injection of saline (control diet and
0.3% DMF diet), 2.0mgkg
 1 MMC (control diet and 0.3% DMF diet) or
3.5mgkg
 1 MMC (control diet only). In addition, some mice on the 0.3%
DMF diet received a single i.p. injection of 34mgkg
 1 DIC 1h prior to the
2.0mgkg
 1 MMC injection. On days 0, 3, 7, 10, 15 and 18, tumour volumes
were measured using digital calipers. The points represent the mean
tumour volume7s.d. of 6–14 mice. The lines are linear regression lines.
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sMice fed control diet and treated with MMC showed a dose-
dependent decrease in WBC counts with the nadir occurring 3 days
after MMC treatment (Figure 4). WBC counts recovered to control
levels by 6 days after drug treatment. Mice fed DMF diet and
treated with 2.0mgkg
 1 MMC showed a similar decrease in WBC
counts as mice fed control diet and treated with 2.0mgkg
 1 MMC.
DMF diet without MMC treatment had no effect on WBC count
(data not shown).
No significant decreases in platelet counts were observed in any
of the groups of mice in the 15 days following MMC treatment
(Figure 5). DMF diet without MMC treatment had no effect on
platelet count (data not shown). There were no significant
differences in body weight in the different treatment groups at
18 days after MMC treatment (data not shown).
In another experiment, CD-1 nude mice received either control
experimental diet or diet containing 0.3% DMF for 7–10 days. The
mice were then treated with saline or 2.0mgkg
 1 MMC and the
animals were euthanised 7 days later. Histological analysis of
tissues from these mice showed no evidence of damage to kidney,
liver, lung, heart, colon or forestomach tissues in the MMC treated
mice fed either control or DMF. Furthermore, treatment with
2.0mgkg
 1 MMC did not produce any significant changes in
blood chemistry in mice fed control or DMF diet (Table 2).
DISCUSSION
MMC is an anticancer agent that has proved to be most effective in
the front line treatment of a small number of solid tumours, such
as superficial bladder, gastric, pancreatic, anal, oesophageal and
non-small-cell cancer (Remers, 1979, pp 27–32; Doll et al, 1985;
Begleiter, 2000). It is also used in palliative treatment of advanced
or resistant cancers, generally in combination regimens (Begleiter,
2000). There has been continued interest in increasing the
effectiveness of this agent because of its activity in solid tumours
and its enhanced effectiveness against hypoxic cells that are
resistant to radiation (Workman and Stratford, 1993).
Use of MMC in the clinic has been severely restricted by its
toxicity (Hortobagyi, 1993; Begleiter, 2000). The usual dose-
limiting toxicity is myelosuppression, which occurs 3–4 weeks
after drug administration, with recovery within 8 weeks (Begleiter,
2000). Generally, thrombocytopenia or leukopenia is most severe,
but anemia is also common. Less common, but potentially serious
or fatal toxicities associated with MMC use include severe
pulmonary toxicity that occurs in 5% of patients (Doll et al,
1985; Begleiter, 2000), and cancer-associated haemolytic–uremic
syndrome, which can occur in 4–15% of patients (Doll et al, 1985;
Begleiter, 2000). In addition, some cases of severe congestive heart
failure have been reported after MMC treatment in patients
previously treated with doxorubicin (Doll et al, 1985).
MMC requires intracellular activation by reductive enzymes like
NQO1 and NADPH cytochrome P450 reductase (Rockwell et al,
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Figure 4 Effect of DMF diet on MMC toxicity to WBC in CD-1 nude
mice. CD-1 nude mice were implanted with HCT116 cells subcutaneously
in the right flank of each mouse. After 7–10 days the mice were fed diet
containing 0 or 0.3% DMF for 7–10 days. The mice were weighed and
received a single tail-vein injection of saline (control diet only), 2.0mgkg
 1
MMC (control diet and 0.3% DMF diet) or 3.5mgkg
 1 MMC (control diet
only). On various days, approximately 20ml of blood was collected from
the saphenous vein of some of the mice in each treatment group. The
WBC counts were determined with a Coulter Z2 particle counter and cell
analyser. The points represent the mean WBC count7s.e. of 5–16 mice.
Differences in the WBC counts in different treatment groups were
analysed statistically by ANOVA for each time point.
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Figure 5 Effect of DMF diet on MMC toxicity to platelets in CD-1 nude
mice. CD-1 nude mice were implanted with HCT116 cells subcutaneously
in the right flank of each mouse. After 7–10 days the mice were fed a diet
containing 0 or 0.3% DMF for 7–10 days. The mice were weighed and
received a single tail-vein injection of saline (control diet only), 2.0mgkg
 1
MMC (control diet and 0.3% DMF diet) or 3.5mgkg
 1 MMC (control diet
only). On various days approximately 20ml of blood was collected from the
saphenous vein of some of the mice in each treatment group. The platelet
counts were determined with a Coulter Z2 particle counter and cell
analyser. The points represent the mean platelet counts7s.e. of 2–14
mice. Differences in the platelet counts in different treatment groups were
analysed statistically by ANOVA for each time point.
Table 2 Effect of DMF diet and MMC on blood chemistry
Tissue Test MMC DMF+MMC
Liver Alkaline phosphatase Normal Normal
Alanine transaminase Normal Normal
Aspartate transaminase Normal Normal
Gamma-glutamyl transpeptidase Normal Normal
Lactate dehydrogenase Normal Normal
Kidney Serum creatinine Normal Normal
Blood urea nitrogen Normal Normal
Dehydration Sodium Normal Normal
Potassium Normal Normal
Chloride Normal Normal
CD-1 nude mice without tumours were fed a 0 or 0.3% DMF diet for 7–10 days and
then were treated with a single tail-vein injection of saline (control diet), 2.0mgkg
 1
MMC (control diet and 0.3% DMF diet). After 7 days, three mice/group were
anaesthetised and blood was obtained by cardiac puncture. The blood was allowed
to clot and the serum was collected and analysed.
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s1993; Workman and Stratford, 1993). Cells with elevated NQO1
levels are generally more sensitive to MMC (Begleiter et al, 1989;
Marshall et al, 1989; Siegel et al, 1990), and NQO1 can be induced
by a wide variety of dietary and synthetic agents (Talalay et al,
1988; Prestera et al, 1993). We have previously shown that NQO1
activity can be selectively increased in tumour cells compared with
normal cells, and that this enhances MMC cytotoxicity in human
and murine cell lines in vitro (Doherty et al, 1998; Wang et al,
1999). In this study we investigated a novel approach to increasing
the antitumour activity of MMC by using a dietary component to
selectively induce NQO1 activity in tumour cells compared with
normal cells. We used DMF, a metabolite of fumaric acid that is
found in fruits and vegetables (Talalay et al, 1988), as the inducer
of NQO1 and HCT116 cells, which have a moderate level of NQO1
activity, as a tumour model. This approach could be used with any
bioreductive agent that is activated by NQO1, but we used MMC
because it is the prototype bioreductive agent and is the only
bioreductive agent in widespread clinical use.
Treatment of HCT116 cells in vitro with DMF for 48h increased
NQO1 activity in these cells by two-fold (Po0.001), and cells that
were pretreated with DMF were 1.4-fold more sensitive to MMC
than cells that were not pretreated (Po0.001). This result was
similar to our previous findings in murine lymphoma cells
(Begleiter et al, 1996) and human breast, lung and colon cancer
cells (Doherty et al, 1998; Wang et al, 1999) using synthetic
inducers of NQO1.
To evaluate the clinical potential of this approach to increasing
the efficacy of MMC, we used a human tumour xenograft mouse
model to investigate whether we could obtain a similar enhance-
ment of antitumour activity in vivo. This model also made it
possible to evaluate any enhanced toxicity that might result from
the NQO1 induction. In addition, the NQO1 inducer, DMF, was
added to the diet of the mice to test the feasibility of this route of
administration. In preliminary studies we found that adding DMF
to the diet of mice resulted in a dose-dependent increase in NQO1
activity in various tissues; however, the increase in enzyme activity
was similar with 0.3 and 0.4% DMF. Thus, 0.3% DMF was used for
subsequent experiments. We also found that NQO1 activity in
HCT116 tumours implanted in CD-1 nude mice reached a plateau
after 7 days on the DMF diet while enzyme activities in other
tissues including kidney, liver, lung and forestomach showed a
further increase at 14 days. Interestingly, there was a very small
increase in NQO1 activity in marrow cells that reached a peak after
3 days and declined thereafter. Therefore, for subsequent
experiments, mice were fed DMF containing diet for 7–10 days
prior to MMC treatment.
NQO1 activity was increased 2.5-fold in the tumours of mice fed
a diet containing 0.3% DMF compared with mice fed control diet;
however, there were similar increases in NQO1 activity in the
kidneys and forestomachs of the inducer fed mice. In contrast,
there were only small increases in NQO1 activity in the livers of
DMF fed mice, and enzyme activity did not increase significantly
in the bone marrow, lungs and hearts. The level of induction of
NQO1 in the tumours was similar to that observed previously in
vitro, and the lack of enzyme induction in the bone marrow was
important as marrow toxicity is the dose-limiting toxicity for MMC
in the clinic. The 2.5-fold increase in NQO1 in the kidneys and
forestomach of the mice is of some concern due to the cancer-
associated haemolytic–uremic syndrome and gastrointestinal
toxicity (Doll et al, 1985; Begleiter, 2000) that occurs in some
patients treated with MMC.
Treatment with 2.0mgkg
 1 MMC did not affect tumour growth
in mice fed control diet. In contrast, 3.5mgkg
 1 MMC signifi-
cantly inhibited tumour growth in mice fed control diet
(Po0.001). However, treatment with 2.0mgkg
 1 MMC in mice
fed DMF diet significantly inhibited tumour growth (Po0.01) to a
level that was similar to that produced by 3.5mgkg
 1 MMC in
mice fed control diet. Thus, the DMF diet enhanced the antitumour
activity of MMC by nearly two-fold. The finding that treatment of
the mice with the NQO1 inhibitor, DIC, prior to MMC partially
reversed the enhanced antitumour activity in DMF fed mice
strongly supports the hypothesis that the increased antitumour
activity was due to the increased NQO1 activity in the tumour. This
result provides strong evidence that the antitumour activity of
bioreductive agents like MMC can be enhanced by induction of
NQO1 in vivo.
MMC doses of 2.0 and 3.5mgkg
 1 MMC decreased WBC counts
by 25 and 45%, respectively, 3 days after drug treatment in control
fed mice, but the counts recovered approximately 6 days after
treatment. There was a further increase in WBC counts in the mice
treated with 3.5mgkg
 1 that reached 150% of normal levels 12
days after MMC treatment, but the counts returned to normal 3
days later. These results are similar to findings reported previously
for the effect of MMC treatment in mice (Shimomura et al, 1988).
WBC counts decreased 3 days after treatment in mice fed DMF diet
and treated with 2.0mgkg
 1, but this effect was not greater than
that seen in mice fed control diet and receiving 2.0mgkg
 1 MMC.
In contrast, while there was some variation with time, we did not
observe any significant decrease in platelet counts in any of the
treatment groups. This result differs somewhat from previous
studies that found a decrease in platelet counts in mice treated with
MMC with the nadir occurring at approximately 7 days following
drug treatment (Shimomura et al, 1988). This difference may be
due to the relatively low dose of MMC used in this study or to
differences in the type of mice used. Overall, these results
demonstrated that induction of NQO1 with DMF did not increase
MMC marrow toxicity.
We found no significant weight loss in mice treated with
2.0mgkg
 1 MMC whether they were fed control or DMF diet. In
addition, there was no histological evidence of damage to kidney,
liver, lung, heart, colon or forestomach tissue in MMC treated
mice that were fed either control or DMF diet. Furthermore,
blood chemistry was normal in mice in all the treatment
groups indicating no damage to the kidneys or livers. This
was true despite the increase in NQO1 activity observed in
kidney and forestomach tissues. This lack of effect may reflect
the dose of MMC used, but demonstrates that induction of NQO1
does not result in toxicity when combined with subtoxic doses of
MMC.
To examine the limits of these findings we treated some DMF
fed mice with 3.5mgkg
 1 MMC (data not shown). We saw almost
no tumour growth in these mice, but we did observed a delayed
weight loss in some of the mice starting at approximately 8 days
after MMC treatment. However, there was no evidence of any
damage to the kidneys, livers, lungs, hearts, forestomach or the
entire gastrointestinal tract by histological examination, or
changes in blood chemistry. Nor did we observe any changes in
food consumption or changes in sodium or potassium levels that
would indicate dehydration in the mice. The cause of the observed
weight loss in these mice remains unknown. There have been some
reports of anorexia associated with MMC use in the clinic, but the
cause of this effect is also unknown. Thus, it is not clear whether
the weight loss we observed in the DMF fed mice receiving
3.5mgkg
 1 MMC would be restricted to mice or would also be a
concern in humans. In addition, it should be noted that the
potential toxic effects of combining DMF diet with MMC were
studied in a mouse model, while the antitumour effects were
studied in human tumours. Although we have previously shown
that induction of NQO1 in human and murine tumours and in
human and murine bone marrow cells is similar (Begleiter et al,
1996; Doherty et al, 1998), induction of NQO1 in other human
tissues has not been extensively studied. This suggests that caution
should be used in applying this approach to enhancing the
antitumour activity of MMC in the clinic.
These studies demonstrated that dietary inducers can be used to
selectively increase the level of NQO1 activity in tumours.
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tive antitumour agent that is activated by NQO1 can significantly
enhance the antitumour activity of the agent in vivo without
increasing toxicity. In the case of MMC, this approach might best
be used by combining an NQO1 inducer with a reduced dose of
MMC. This would produce an antitumour effect that was
equivalent to the normal dose of MMC with reduced toxicity,
especially myelosuppression, resulting in a faster recovery time
and allowing more frequent retreatment. The use of a dietary
component to induce NQO1 would also facilitate clinical evalua-
tion of this strategy. In this study, we observed a two-fold
enhancement of MMC antitumour activity. While this effect is
relatively small, it could have a significant clinical impact if the
combination therapy were used as described above. However,
NQO1 is not the most important activating enzyme for MMC and
may contribute only approximately 30% to its activation (Rockwell
et al, 1993). Thus, induction of NQO1 might produce a greater
enhancement of antitumour activity, and an even greater clinical
effect, when combined with a bioreductive agent like RH1, which is
selectively activated by NQO1 (Winski et al, 1998). Studies to
investigate this possibility are in progress.
ACKNOWLEDGEMENTS
Supported by grants from the National Cancer Institute of Canada
with funds from the Canadian Cancer Society, the Canadian
Institutes of Health Research and the American Institute for
Cancer Research.
REFERENCES
Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J, Ross D (1995)
Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase
(DT-diaphorase) as a target for bioreductive antitumor quinones:
quinone cytotoxicity and selectivity in human lung and breast cancer
cell lines. Mol Pharmacol 48: 499–504
Begleiter A (2000) Clinical applications of quinone alkylating agents. Front
Biosci 5: e153–e171
Begleiter A, Leith MK (1993) Role of NAD(P)H:(quinone acceptor)
oxidoreductase (DT-diaphorase) in activation of mitomycin C under
acidic conditions. Mol Pharmacol 44: 210–215
Begleiter A, Leith MK, Curphey TJ (1996) Induction of DT-diaphorase by
1,2-dithiole-3-thione and increase of antitumour activity of bioreductive
agents. Br J Cancer 74(Suppl 27): S9–S14
Begleiter A, Robotham E, Lacey G, Leith MK (1989) Increased sensitivity of
quinone resistant cells to mitomycin C. Cancer Lett 45: 173–176
Begleiter A, Robotham E, Leith MK (1992) Role of NAD(P)H:(quinone
acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C
under hypoxia. Mol Pharmacol 41: 677–682
Belinsky M, Jaiswal AK (1993) NAD(P)H:quinone oxidoreductase1 (DT-
diaphorase) expression in normal and tumour tissues. Cancer Metastasis
Rev 12: 103–117
Collard J, Mathew AM, Double JA, Bibby MC (1995) EO9: relationship
between DT-diaphorase levels and response in vitro and in vivo. Br J
Cancer 71: 1199–1203
Doherty GP, Leith MK, Wang X, Curphey TJ, Begleiter A (1998) Induction
of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and
normal cells and effect on antitumor activity of bioreductive agents. Br
J Cancer 77: 1241–1252
Doll DC, Weiss RB, Issell BF (1985) Mitomycin: ten years after approval for
marketing. J Clin Oncol 3: 276–286
Dusre L, Covey JM, Collins C, Sinha BK (1989) DNA damage, cytotoxicity
and free radical formation by mitomycin C in human cells. Chem–Biol
Interactions 71: 63–78
Egner PA, Kensler TW, Prestera T, Talalay P, Libby AH, Joyner HH,
Curphey TJ (1994) Regulation of phase 2 enzyme induction by oltipraz
and other dithiolethiones. Carcinogenesis 15: 177–181
Ernster L (1987) DT-diaphorase: a historical review. Chem Scr 27A: 1–13
Favreau LV, Pickett CB (1993) Transcriptional regulation of the rat
NAD(P)H:quinone reductase gene. characterization of a DNA–protein
interaction at the antioxidant responsive element and induction by
12-o-tetradecanoylphorbol 13-acetate. J Biol Chem 268: 19875–19881
Hecht SS (1998) Chemoprevention by isothiocyanates. J Cell Biochem
22(Suppl): 195–209
Hem A, Smith AJ, Solberg P (1998) Saphenous vein puncture for blood
sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink.
Lab Anim 32: 364–368
Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P,
Harris AL, Hickson ID (1990) Decreased NADPH:cytochrome P-450
reductase activity and impaired drug activation in a mammalian cell line
resistant to mitomycin C under aerobic but not hypoxic conditions.
Cancer Res 50: 4692–4697
Hortobagyi GN (1993) Mitomycin: Its evolving role in the treatment of
breast cancer. Oncology (Basel) 50(Suppl 1): 1–8
Jaiswal AK (1991) Human NAD(P)H:quinone oxidoreductase
(NQO-1) gene structure and induction by dioxin. Biochemistry 30:
10647–10653
Jaiswal AK, Burnett P, Adesnik M, McBride OW (1990) Nucleotide and
deduced amino acid sequence of a human cDNA (NQO2) corresponding
to a second member of the NAD(P)H:quinone oxidoreductase gene
family. Extensive polymorphism at the NQO2 gene locus on chromosome
6. Biochemistry 29: 1899–1906
Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen BB, Wang JS,
Zhu YR, Zhang BC, Wang JB, Wu Y, Zhang QN, Qian GS, Kuang SY, Fang
X, Li YF, Yu LY, Prochaska HJ, Davidson NE, Gordon GB, Gorman MB,
Zarba A, Enger C, Munoz A (1998) Oltipraz chemoprevention trial in
Qidong, People’s Republic of China: modulation of serum aflatoxin
albumin adduct biomarkers. Cancer Epidemiol Biomark Prev 7: 127–134
Kepa JK, Ross D (1999) DT-diaphorase activity in NSCLC and SCLC cell
lines: a role for fos/jun regulation. Br J Cancer 79: 1679–1684
Lown JW, Begleiter A, Johnson D, Morgan AR (1976) Studies related to
antitumor antibiotics. Part V. Reaction of mitomycin C with DNA
examined by ethidium fluorescence assay. Can J Biochem 54: 110–119
Marshall RS, Paterson MC, Rauth AM (1989) Deficient activation by a
human cell strain leads to mitomycin resistance under aerobic but not
hypoxic conditions. Br J Cancer 59: 341–346
Nguyen T, Huang HC, Pickett CB (2000) Transcriptional regulation of the
antioxidant response element. J Biol Chem 275: 15466–15473
Pan SS, Andrews PA, Glover CJ, Bachur NR (1984) Reductive activation of
mitomycin C and mitomycin C metabolites catalyzed by NADPH-
cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 259:
959–966
Pan SS, Iracki T, Bachur NR (1986) DNA alkylation by enzyme-activated
mitomycin C. Mol Pharmacol 29: 622–628
Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ
(1995) Importance of P450 reductase activity in determining sensitivity
of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Br J Cancer 72: 1144–1150
Prestera T, Zhang Y, Spencer SR, Wilczak CA, Talalay P (1993) The
electrophile counterattack response: protection against neoplasia and
toxicity. Adv Enzyme Regul 33: 281–296
Rauth AM, Marshall RS, Kuehl BL (1993) Cellular approaches to
bioreductive drug mechanisms. Cancer Metastasis Rev 12: 153–164
Rauth AM, Melo T, Misra V (1998) Bioreductive therapies: an overview of
drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 42:
755–762
Remers WA (1979) Mitomycin C and analog development. In Mitomycin C
Current Status and New Developments Carter SK, Crooke ST (eds). pp
27–32, New York: Academic Press
Riley RJ, Workman P (1992) DT-diaphorase and cancer chemotherapy.
Biochem Pharmacol 43: 1657–1669
Rockwell SC, Kallman RF, Fajardo LF (1972) Characteristics of a serially
transplanted mouse mammary tumor and its tissue-culture-adapted
derivative. J Natl Cancer Inst 49: 735–747
Rockwell S, Sartorelli AC, Tomasz M, Kennedy KA (1993) Cellular
pharmacology of quinone bioreductive alkylating agents. Cancer Metast
Rev 12: 165–176
Increasing mitomycin C activity by inducing NQO1 in vivo
A Begleiter et al
1630
British Journal of Cancer (2004) 91(8), 1624–1631 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sRoss D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW (1994)
Bioactivation of quinones by DT-diaphorase, molecular, biochemical,
and chemical studies. Oncol Res 6: 493–500
Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW (1993) DT-
diaphorase in activation and detoxification of quinones. Cancer Metast
Rev 12: 83–101
Schlager JJ, Powis G (1990) Cytosolic NAD(P)H:(quinone-acceptor)oxidor-
eductase in human normal and tumor tissue: effects of cigarette smoking
and alcohol. Int J Cancer 45: 403–409
Shimomura K, Manda T, Mukumoto S, Masuda K, Nakamura T, Mozota T,
Matsumoto S, Nishigali F, Oku T, Mori J, Shibayama F (1988) Antitumor
activity and hematotoxicity of a new, substituted dihydrobenzoxazine,
FK973, in mice. Cancer Res 48: 1166–1172
Siegel D, Gibson NW, Preusch PC, Ross D (1990) Metabolism of mitomycin
C by DT-diaphorase: role in mitomycin C-induced DNA damage and
cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483–7489
Siegel S, Ryder J, Ross D (2001) NAD(P)H: quinone oxidoreductase 1
expression in human bone marrow endothelial cells. Toxicol Lett 125:
93–98
Talalay P, De Long MJ, Prochaska HJ (1988) Identification of a common
chemical signal regulating the induction of enzymes that protect against
chemical carcinogenesis. Proc Natl Acad Sci USA 85: 8261–8265
Tomasz M, Lipman R, Chowdary D, Pawlak L, Verdine GL, Nakanishi K
(1987) Isolation and structure of a covalent cross-link adduct between
mitomycin C and DNA. Science (Washington, DC) 235: 1204–1208
Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and c-Fos and
Fra1 negatively regulate the human antioxidant response element-
mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc
Natl Acad Sci USA 93: 14960–14965
Venugopal R, Jaiswal AK (1998) Nrf2 and Nrf1 in association with Jun
proteins regulate antioxidant response element-mediated expression and
coordinated induction of genes encoding detoxifying enzymes. Oncogene
17: 3145–3156
Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A (1999) Enhanced
cytotoxicity of mitomycin C in human tumor cells with inducers of DT-
diaphorase. Br J Cancer 80: 1223–1230
Winski SL, Hargreaves RH, Butler J, Ross D (1998) A new screening
system for NAD(P)H:quinone oxidoreductase (NQO1)-directed
antitumor quinones: identification of a new aziridinylbenzoquinone,
RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 4:
3083–3088
Workman P, Stratford IJ (1993) The experimental development of
bioreductive drugs and their role in cancer therapy. Cancer Metast Rev
12: 73–82
Yao K, O’Dwyer PJ (1995) Involvement of NF-kappa B in the induction of
NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz
and mitomycin. Biochem Pharmacol 49: 275–282
Yao KS, Xanthoudakis S, Curran T, O’Dwyer PJ (1996) Activation of AP-1
and of a nuclear redox factor, Ref-1, in the response of HT29 colon
cancer cells to hypoxia. Mol Cell Biol 14: 5997–6003
Increasing mitomycin C activity by inducing NQO1 in vivo
A Begleiter et al
1631
British Journal of Cancer (2004) 91(8), 1624–1631 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s